Drug Profile
Research programme: cancer therapeutics - Celgene
Alternative Names: CNX-1351; CNX-222; Targeted covalent drugs for cancer - Celgene/SanofiLatest Information Update: 03 Dec 2019
Price :
$50
*
At a glance
- Originator Avila Therapeutics
- Developer Celgene Corporation
- Class Small molecules
- Mechanism of Action ERBB-3 receptor antagonists; Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 07 Mar 2012 Avila Therapeutics has been acquired by Celgene Corporation